ZYNLONTA combo trials in r/r DLBCL, key LOTIS-5 data Q2 2026, strong ORR/CR, cash to 2028—read now. Click for this ADCT ...
These findings are important because they suggest that more selective JAK inhibition, particularly targeting JAK1 or JAK2, can effectively reduce organ pathology and pathogenic IFN-γ-producing immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results